In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 4, No. 12 ( 1986-12), p. 1799-1803
Abstract:
In a phase II multicenter trial, 71 patients with advanced measurable gastric cancer were registered to receive sequential high-dose methotrexate (MTX) and 5-fluorouracil (5-FU) combined with Adriamycin (A [Adria Laboratories, Columbus, OH]). The response rate was 33% (22 of 67), including all eligible patients. There were nine complete responders (CRs). The median survival for all patients was 6 months. There has been one toxic death; however, three other patients died from toxicity associated with major protocol violations. It is concluded that this protocol is active in gastric cancer. Toxicity, partly because of nonprotocol adherence, is considerable and is now under further investigation in a randomized trial comparing this schedule with a combination of 5-FU, Adriamycin, and mitomycin C (FAM).
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.1986.4.12.1799
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
1986
detail.hit.zdb_id:
2005181-5
Bookmarklink